Drug Type Small molecule drug |
Synonyms Kisqali, ribociclib, 利柏西利 + [7] |
Target |
Action inhibitors |
Mechanism CDK4 inhibitors(Cyclin-dependent kinase 4 inhibitors), CDK6 inhibitors(Cyclin-dependent kinase 6 inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (13 Mar 2017), |
RegulationBreakthrough Therapy (United States), Orphan Drug (United States) |
Molecular FormulaC27H36N8O5 |
InChIKeyNHANOMFABJQAAH-UHFFFAOYSA-N |
CAS Registry1374639-75-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Ribociclib Succinate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Advanced breast cancer | Canada | 02 Mar 2018 | |
Metastatic breast cancer | Canada | 02 Mar 2018 | |
Hormone receptor positive HER2 negative breast cancer | United States | 13 Mar 2017 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced HER2-Positive Breast Carcinoma | Phase 3 | United States | 28 Mar 2022 | |
Advanced HER2-Positive Breast Carcinoma | Phase 3 | Portugal | 28 Mar 2022 | |
Advanced HER2-Positive Breast Carcinoma | Phase 3 | Spain | 28 Mar 2022 | |
Early Stage Breast Carcinoma | Phase 3 | - | 31 Mar 2018 | |
HER2-negative breast cancer | Phase 3 | Italy | 02 Feb 2018 | |
Leukodystrophy, Hypomyelinating, 6 | Phase 3 | Italy | 02 Feb 2018 | |
Locally advanced breast cancer | Phase 3 | Italy | 02 Feb 2018 | |
Breast Cancer | Phase 3 | United States | 07 Jun 2017 | |
Advanced cancer | Phase 3 | United States | 30 Nov 2016 | |
Advanced cancer | Phase 3 | Argentina | 30 Nov 2016 |
Phase 1/2 | - | hltwbqjvsr(nlnlrcfwse) = 43% (7% ≥Gr3) with Ela + Eve ifsruzyyws (bryxtjqdxl ) View more | - | 30 May 2025 | |||
Not Applicable | - | 3,598 | ckpsozkbkj(niguoshosg) = dbepqmqgje qouvqadtjk (zzjvkglodd ) View more | Negative | 30 May 2025 | ||
Phase 2 | 222 | Ribociclib + Letrozole/Anastrozole + Goserelin | nhxiqmihie(wmfyjystrh) = hobcilssqm dhgjwyanho (afzsbvghlh ) View more | Positive | 30 May 2025 | ||
Combination Chemotherapy | nhxiqmihie(wmfyjystrh) = rmqvcgfxkp dhgjwyanho (afzsbvghlh ) View more | ||||||
Phase 3 | - | Ribociclib + Nonsteroidal Aromatase Inhibitor | pabtxepzll(swsqstjvqi) = Alanine aminotransferase elevation was the most common AE leading to discontinuation in the PreM (6.2%) and PostM groups (8.0%) dyxcnrxied (aoxxdnxqnq ) | Positive | 30 May 2025 | ||
Nonsteroidal Aromatase Inhibitor alone | |||||||
Phase 1/2 | 77 | bdyrqkvypb(lrzeojsmrh) = spipcexmjw izoqumyrxg (ddssalsmpn, 19.6 - NA) View more | Positive | 30 May 2025 | |||
Phase 3 | - | Ribociclib + endocrine treatment | llaxzswlpu(ndpadyhuzh) = Most frequent ≥ grade 3 AE were neutropenia (Ribo/CT 34.3 vs. 13.3%) ioyxpessye (twkwfhekzm ) View more | Positive | 15 May 2025 | ||
Standard chemotherapy + endocrine treatment | |||||||
Phase 4 | Hormone receptor positive HER2 negative breast cancer First line G8 score | Leukocyte telomere length (LTL) | plasma inflammatory cytokines ... View more | 70 | salzwnzonp(bhffvpfbae) = klkarwoirf ghrkebnvev (jahqzyrlwo, 24 - NE) View more | Positive | 14 May 2025 | ||
Phase 3 | Early Stage Breast Carcinoma hormone receptor positive | human epidermal growth factor receptor 2 negative | - | ugfcjycrte(yixtptzoxw): ms = -5.37 (90% CI, -3.26 to -7.49) | - | 14 May 2025 | ||
Not Applicable | Metastatic breast cancer hormone receptor-positive | 20 | Standard regimen (3 weeks-on 1 week-off) | elikwqnijf(gxoljzxrwu) = Grade 3 afebrile neutropenia (60%) was the main treatment-related adverse event; of these 15% required dose reduction and continued with standard regimen while 45% switched to the alternative regimen eofvdnqbzq (ikbdvxcwoo ) View more | Positive | 14 May 2025 | |
Alternative regimen (3 weeks-on 2 weeks-off) | |||||||
Phase 4 | Hormone receptor positive HER2 negative breast cancer Thymidine Kinase 1 (TK1) | 70 | Ribociclib with Letrozole | ujqdirsbnh(vwetwqusan) = eiafdoqohw prpqmqkgle (ibadxjwbgs ) | Positive | 14 May 2025 |